MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318879 | Name: Tirofiban HCl hydrate
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tirofiban is an antiplatelet drug. It belongs to a class of antiplatelet named glycoprotein IIb/IIIa inhibitors. Tirofiban is the first drug candidate whose origins can be traced to a pharmacophore-based virtual screening lead. Tirofiban is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Chemical Structure

Tirofiban HCl hydrate
Tirofiban HCl hydrate
CAS#150915-40-5 (HCl hydrate)

Theoretical Analysis

MedKoo Cat#: 318879

Name: Tirofiban HCl hydrate

CAS#: 150915-40-5 (HCl hydrate)

Chemical Formula: C22H39ClN2O6S

Exact Mass: 440.2345

Molecular Weight: 495.07

Elemental Analysis: C, 53.37; H, 7.94; Cl, 7.16; N, 5.66; O, 19.39; S, 6.48

Price and Availability

Size Price Availability Quantity
100mg USD 650.00 2 Weeks
250mg USD 1,250.00 2 Weeks
500mg USD 1,950.00 2 Weeks
1g USD 2,950.00 2 Weeks
2g USD 4,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
150915-40-5 (HCl hydrate) 144494-65-5 (free base) 142373-60-2 (HCl)
Synonym
Aggrastat; L 700462; L-700,462; MK-383; MK 383; MK383; Tirofiban; Tirofiban hydrochloride monohydrate.
IUPAC/Chemical Name
N-(Butylsulfonyl)-4-(4-(4-piperidyl)butoxy)-L-phenylalanine monohydrochloride monohydrate
InChi Key
HWAAPJPFZPHHBC-FGJQBABTSA-N
InChi Code
InChI=1S/C22H36N2O5S.ClH.H2O/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18;;/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26);1H;1H2/t21-;;/m0../s1
SMILES Code
O=C(O)[C@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)NS(=O)(CCCC)=O.[H]Cl.[H]O[H]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# CAS#150915-40-5 (Tirofiban HCl, monohydrate) CAS#144494-65-5 (Tirofiban free base)

Preparing Stock Solutions

The following data is based on the product molecular weight 495.07 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wang J, Zou D. Tirofiban-induced thrombocytopenia. Ann Med. 2023 Dec;55(1):2233425. doi: 10.1080/07853890.2023.2233425. PMID: 37439782; PMCID: PMC10348023. 2: Szarpak L, Rafique Z, Gasecka A, Jaguszewski MJ, Filipiak KJ. Tirofiban in emergency conditions. Am J Emerg Med. 2022 Jan;51:422-423. doi: 10.1016/j.ajem.2021.03.063. Epub 2021 Mar 24. PMID: 33824023. 3: Zhao W, Li S, Li C, Wu C, Wang J, Xing L, Wan Y, Qin J, Xu Y, Wang R, Wen C, Wang A, Liu L, Wang J, Song H, Feng W, Ma Q, Ji X; TREND Investigators. Effects of Tirofiban on Neurological Deterioration in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial. JAMA Neurol. 2024 Jun 1;81(6):594-602. doi: 10.1001/jamaneurol.2024.0868. Erratum in: JAMA Neurol. 2024 Aug 1;81(8):889. doi: 10.1001/jamaneurol.2024.2195. PMID: 38648030; PMCID: PMC11036313. 4: Shi H, Hou MM, Ren G, He ZF, Liu XL, Li XY, Sun B. Tirofiban for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis: A Systematic Review and Meta-Analysis. Cerebrovasc Dis. 2023;52(5):587-596. doi: 10.1159/000527861. Epub 2022 Dec 29. PMID: 36580906. 5: Gong J, Shang J, Yu H, Wan Q, Su D, Sun Z, Liu G. Tirofiban for acute ischemic stroke: systematic review and meta-analysis. Eur J Clin Pharmacol. 2020 Apr;76(4):475-481. doi: 10.1007/s00228-019-02817-8. Epub 2020 Jan 3. PMID: 31900544. 6: Li W, Wu Y, Li XS, Liu CC, Huang SH, Liang CR, Wang H, Zhang LL, Xu ZQ, Wang YJ, Zhang M. Intravenous tirofiban therapy for patients with capsular warning syndrome. Stroke Vasc Neurol. 2019 Jan 9;4(1):22-27. doi: 10.1136/svn-2018-000163. Erratum in: Stroke Vasc Neurol. 2019 Mar 2;4(2):108. doi: 10.1136/svn-2018-000163corr1. PMID: 31105975; PMCID: PMC6475082. 7: Zi W, Song J, Qiu Z, Kong W, Huang J, Luo W, Liu S, Sang H, Yang J, Li L, Tian Y, Hu J, Saver JL, Nogueira RG, Li F, Yang Q. RESCUE BT 2, a multicenter, randomized, double-blind, double-dummy trial of intravenous tirofiban in acute ischemic stroke: Study rationale and design. Int J Stroke. 2023 Jun;18(5):620-625. doi: 10.1177/17474930221122681. Epub 2022 Sep 7. PMID: 35993176. 8: Liu Q, Lu X, Yang H, Deng S, Zhang J, Chen S, Shi S, Xun W, Peng R, Lin B, Li T, Pan L, Weng B. Early tirofiban administration for patients with acute ischemic stroke treated with intravenous thrombolysis or bridging therapy: Systematic review and meta-analysis. Clin Neurol Neurosurg. 2022 Nov;222:107449. doi: 10.1016/j.clineuro.2022.107449. Epub 2022 Sep 21. PMID: 36162161. 9: Al-Salihi MM, Ayyad A, Al-Jebur MS, Al-Salihi Y, Saha R, Morsi RZ, Kass-Hout T, Kasab SA, Spiotta AM. Safety and efficacy of tirofiban in the management of stroke: A systematic review and meta-analysis of randomized controlled trials. Clin Neurol Neurosurg. 2023 Sep;232:107867. doi: 10.1016/j.clineuro.2023.107867. Epub 2023 Jun 29. PMID: 37423089. 10: Liu YY, Dong QT, Guo YL, Wu NQ, Li JJ. Tirofiban-Induced Severe Thrombocytopenia. Am J Ther. 2019 Sep/Oct;26(5):e659-e661. doi: 10.1097/MJT.0000000000000861. PMID: 31356349. 11: Yang M, Huo X, Miao Z, Wang Y. Platelet Glycoprotein IIb/IIIa Receptor Inhibitor Tirofiban in Acute Ischemic Stroke. Drugs. 2019 Apr;79(5):515-529. doi: 10.1007/s40265-019-01078-0. PMID: 30838514. 12: Juwana YB, Suryapranata H, Ottervanger JP, van 't Hof AW. Tirofiban for myocardial infarction. Expert Opin Pharmacother. 2010 Apr;11(5):861-6. doi: 10.1517/14656561003690005. PMID: 20210689. 13: Huang J, Kong W, Liu C, Song J, Yang J, Yue C, Li L, Hu J, Tian Y, Peng Z, Guo C, Yang D, Liu X, Miao J, Zhang X, Li F, Saver JL, Zi W. Intravenous tirofiban following successful reperfusion in intracranial large artery atherosclerotic stroke: A secondary analysis of a randomized clinical trial. Ann Clin Transl Neurol. 2023 Nov;10(11):2043-2052. doi: 10.1002/acn3.51891. Epub 2023 Aug 30. PMID: 37649303; PMCID: PMC10646994. 14: de Oliveira MPR, Sandes PHF, de Souza DCR, Piñeiro GTO, Medrado-Nunes GS, Dos Santos NSSF, Oliveira-Filho J. Tirofiban vs. aspirin in patients with acute ischemic stroke: A meta-analysis of randomized clinical trials. Clin Neurol Neurosurg. 2024 Dec;247:108626. doi: 10.1016/j.clineuro.2024.108626. Epub 2024 Oct 31. PMID: 39488985. 15: Wu C, Sun C, Wang L, Lian Y, Xie N, Huang S, Zhao W, Ren M, Wu D, Ding J, Song H, Wang Y, Ma Q, Ji X. Low-Dose Tirofiban Treatment Improves Neurological Deterioration Outcome After Intravenous Thrombolysis. Stroke. 2019 Dec;50(12):3481-3487. doi: 10.1161/STROKEAHA.119.026240. Epub 2019 Oct 1. PMID: 31570084. 16: Tang L, Tang X, Yang Q. The Application of Tirofiban in the Endovascular Treatment of Acute Ischemic Stroke: A Meta-Analysis. Cerebrovasc Dis. 2021;50(2):121-131. doi: 10.1159/000512601. Epub 2021 Jan 5. PMID: 33401276. 17: Zhou J, Gao Y, Ma QL. Safety and efficacy of tirofiban in acute ischemic stroke patients not receiving endovascular treatment: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2020 Feb;24(3):1492-1503. doi: 10.26355/eurrev_202002_20208. PMID: 32096199. 18: Zhang ZM, Lin ZH, Zhu GL. Tirofiban in the treatment of cancer-associated ischemic stroke. Eur Rev Med Pharmacol Sci. 2023 Apr;27(8):3590-3596. doi: 10.26355/eurrev_202304_32142. PMID: 37140310. 19: Rong B, Guo Z, Gao L, Yang Y, Zi W, Qiu Z, Li F, Lv Z, Luo Y, Meng R, Xie Y, Long T, Zhang S, Jiang J, Tian J, Zhao J, Zeng H, Yuan Z. Association of tirofiban treatment with outcomes following endovascular therapy in cardioembolic stroke: insights from the RESCUE BT randomized trial. Eur J Med Res. 2023 Nov 1;28(1):473. doi: 10.1186/s40001-023-01406-x. PMID: 37915101; PMCID: PMC10621173. 20: Lu WZ, Lin HA, Hou SK, Bai CH, Lin SF. Efficacy and safety of tirofiban in patients with acute ischemic stroke treated with endovascular thrombectomy: A frequentist and Bayesian meta-analysis. Vascul Pharmacol. 2023 Dec;153:107244. doi: 10.1016/j.vph.2023.107244. Epub 2023 Nov 21. PMID: 37992511.